[Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].
作者信息
Du J, Hou Jian
机构信息
Department of Hematology, Shanghai Changzheng Hospital, Shanghai 200003,China.
Department of Hematology,Shanghai Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200120, China.
出版信息
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):463-465. doi: 10.3760/cma.j.cn112138-20220316-00182.
Abstract
摘要
相似文献
1
[Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].[中国多发性骨髓瘤诊断与治疗指南（2022年修订版）中多发性骨髓瘤诊断的解读]
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):463-465. doi: 10.3760/cma.j.cn112138-20220316-00182.
2
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of the treatment of relapsing and refractory multiple myeloma].中国多发性骨髓瘤诊断与治疗指南（2015年修订版）：复发/难治性多发性骨髓瘤治疗解读
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):93-4. doi: 10.3760/cma.j.issn.0578-1426.2016.02.004.
3
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of diagnosis].《中国多发性骨髓瘤诊治指南（2015年修订版）：诊断解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):91-2. doi: 10.3760/cma.j.issn.0578-1426.2016.02.002.
4
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of initial treatment].《中国多发性骨髓瘤诊治指南（2015年修订版）：初始治疗解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):92-3. doi: 10.3760/cma.j.issn.0578-1426.2016.02.003.
5
[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of response criteria].《中国多发性骨髓瘤诊治指南（2015年修订版）：疗效标准解读》
Zhonghua Nei Ke Za Zhi. 2016 Feb;55(2):94-6. doi: 10.3760/cma.j.issn.0578-1426.2016.02.005.
6
[Interpretation of treatment of relapsed/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China(2022 revision)].[《中国多发性骨髓瘤诊断与治疗指南（2022年修订版）》中复发/难治性多发性骨髓瘤患者的治疗解读]
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):469-473. doi: 10.3760/cma.j.cn112138-20220414-00278.
7
[Interpretation of treatment for newly diagnosed multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].
Zhonghua Nei Ke Za Zhi. 2022 May 1;61(5):465-469. doi: 10.3760/cma.j.cn112138-20220309-00162.
8
[Interpretation of minimal residual disease monitoring for response evaluation in "the guidelines for the diagnosis and management of multiple myeloma in China(2020 revision)"].《解读<中国多发性骨髓瘤诊断与治疗指南（2020年修订版）>中微小残留病监测用于疗效评估》
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):332-334. doi: 10.3760/cma.j.cn112138-20200217-00084.
9
[Best wishes to the guidelines for the diagnosis and management of multiple myeloma in China (2020 revision)].[祝《中国多发性骨髓瘤诊断与治疗指南（2020年修订版）》顺利]
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):329-331. doi: 10.3760/cma.j.cn112138-20200309-00208.
10
[The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision)].中国多发性骨髓瘤诊断与治疗指南（2017年修订版）
Zhonghua Nei Ke Za Zhi. 2017 Nov 1;56(11):866-870. doi: 10.3760/cma.j.issn.0578-1426.2017.11.021.
Zotero 插件